Loading…
Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation11NIH grants CA 82422 and 1RO1 CA 83867 (P. A. J.), NIH Training Grant T32 DE07211-11 (M. V.), and NIH Training Grant in Basic Research in Oncology T32 CA09659 (D. W.).Note: D. J. Weisenberger and M. Velicescu contributed equally to this work
Several alternatively spliced variants of DNA methyltransferase (DNMT) 3b have been described. Here, we identified new murine Dnmt3b mRNA isoforms and found that mouse embryonic stem (ES) cells expressed only Dnmt3b transcripts that contained exons 10 and 11, whereas the Dnmt3b transcripts in somati...
Saved in:
Published in: | Molecular cancer research 2004-01, Vol.2 (1), p.62 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Several alternatively spliced variants of DNA methyltransferase (DNMT) 3b have been described. Here, we identified new murine
Dnmt3b mRNA isoforms and found that mouse embryonic stem (ES) cells expressed only Dnmt3b transcripts that contained exons
10 and 11, whereas the Dnmt3b transcripts in somatic cells lacked these exons, suggesting that this region is important for
embryonic development. DNMT3b2 and 3b3 were the major isoforms expressed in human cell lines and the mRNA levels of these
isoforms closely correlated with their protein levels. Although DNMT3b3 may be catalytically inactive, it still may be biologically
important because D4Z4 and satellites 2 and 3 repeat sequences, all known DNMT3b target sequences, were methylated in cells that predominantly expressed
DNMT3b3. Treatment of cells with the mechanism-based inhibitor 5-aza-2′-deoxycytidine (5-Aza-CdR) caused a complete depletion
of DNMT1, 3a, 3b1, and 3b2 proteins. Human DNMT3b3 and the murine Dnmt3b3-like isoform, Dnmt3b6, were also depleted although
less efficiently, suggesting that DNMT3b3 also may be capable of DNA binding. Moreover, de novo methylation of D4Z4 in T24 cancer cells after 5-Aza-CdR treatment only occurred when DNMT3b3 was expressed, reinforcing its role as a contributing
factor of DNA methylation. The expression of either DNMT3b2 or 3b3, however, was not sufficient to explain the abnormal methylation
of DNMT3b target sequences in human cancers, which may therefore be dependent on factors that affect DNMT3b targeting. Methylation
analyses of immunodeficiency, chromosomal instabilities, and facial abnormalities cells revealed that an Alu repeat sequence
was highly methylated, suggesting that Alu sequences are not DNMT3b targets. |
---|---|
ISSN: | 1541-7786 1557-3125 |